India to launch national program to control viral hepatitis and aims to negotiate lower drug prices
Taking a cue from the state governments of Haryana and Punjab, which have negotiated the price of hepatitis C drugs and started free treatment of hepatitis C patients in their jurisdiction, India's health ministry is looking to negotiate the price of the drug for inclusion in a national program. The ministry is in talks with Indian companies which manufacture sofosbuvir on behalf of American biotech giant Gilead Sciences (Nasdaq: GILD), reports The Pharma Letter’s India correspondent.
About 12 million people are reported to be suffering from hepatitis C in the country, six times the number of HIV/AIDS patients.
The health ministry is set to roll out a National Program for the Control of Viral Hepatitis from the 2018-19 financial year. An antiviral treatment that costs anywhere between $63,000 and $94,000 for the full course in the USA and Europe is to be provided free of cost at all government health organizations.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze